Efficacy and Safety Profile of Oral Tofacitinib in Non-Segmental Vitiligo
Background: Vitiligo is a chronic disease that is often challenging to treat. Melanocyte destruction in vitiligo is mediated by immune pathways involving IFN-γ and CD8+ T cells. Tofacitinib, a Janus kinase (JAK) 1/3 inhibitor, can be a promising treatment for vitiligo due to its potential to inhibit...
Gorde:
| Egile Nagusiak: | , , , |
|---|---|
| Formatua: | Artigo |
| Hizkuntza: | Inglês |
| Argitaratua: |
Wolters Kluwer Medknow Publications
2026-05-01
|
| Saila: | Indian Journal of Dermatology |
| Gaiak: | |
| Sarrera elektronikoa: | https://journals.lww.com/10.4103/ijd.ijd_141_25 |
| Etiketak: |
Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!
|